Karyopharm Therapeutics Files Q1 2025 10-Q
Ticker: KPTI · Form: 10-Q · Filed: May 12, 2025 · CIK: 1503802
| Field | Detail |
|---|---|
| Company | Karyopharm Therapeutics Inc. (KPTI) |
| Form Type | 10-Q |
| Filed Date | May 12, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, financials, debt, convertible-notes
TL;DR
Karyopharm's Q1 10-Q shows updated financials, including convertible debt and 2029 notes.
AI Summary
Karyopharm Therapeutics Inc. filed its 10-Q for the period ending March 31, 2025. The company reported on its financial position, including details on its common stock and retained earnings as of December 31, 2023, and March 31, 2025. It also disclosed information regarding its convertible debt and secured convertible senior notes due in 2029.
Why It Matters
This filing provides investors with an update on Karyopharm's financial health and debt obligations, crucial for assessing the company's stability and future prospects.
Risk Assessment
Risk Level: medium — The company's financial disclosures, particularly concerning debt and convertible notes, indicate potential financial risks that warrant careful investor consideration.
Key Numbers
- 2025-03-31 — Reporting Period End Date (Indicates the latest financial snapshot provided.)
- 2023-12-31 — Prior Year End Date (Provides a comparative point for financial trends.)
- 2025-01-30 — Maximum Fair Value Input Date (Relates to the valuation of financial instruments.)
Key Players & Entities
- Karyopharm Therapeutics Inc. (company) — Filer of the 10-Q
- 20250331 (date) — End of reporting period
- 2023-12-31 (date) — Balance sheet date
- 2025-03-31 (date) — Balance sheet date
- kpti:SixPercentageSecuredConvertibleSeniorNotesDueTwoThousandTwentyNineMember (dollar_amount) — Debt instrument
FAQ
What is the total amount of convertible debt reported as of March 31, 2025?
The filing indicates 'us-gaap:ConvertibleDebtMember' as of 2025-03-31, but a specific dollar amount is not provided in this snippet.
What is the maturity date for the 'Six Percentage Secured Convertible Senior Notes'?
The notes are due in 'TwoThousandTwentyNine', as indicated by 'kpti:SixPercentageSecuredConvertibleSeniorNotesDueTwoThousandTwentyNineMember'.
What was the company's retained earnings as of December 31, 2024?
The filing mentions 'us-gaap:RetainedEarningsMember' for '2024-12-31', but the specific value is not detailed in this extract.
What is the context for 'kpti:MaytwoThousandTwentyFourWarrantsMember'?
This relates to warrants issued in May 2024, with a maximum value noted as of March 31, 2025.
Does the filing mention any revenue interest agreements?
Yes, the filing references 'kpti:RevenueInterestAgreementAndAmendedRevenueInterestAgreementMember' as of March 31, 2025.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 12, 2025 regarding Karyopharm Therapeutics Inc. (KPTI).